Relative survival provides a more reliable measure of excess mortality for people diagnosed with cancer. In the general population with cancer, the relative survival has increased to 68% in 2009-13 but estimates for the kidney failure and kidney transplant population with cancer are unknown.

ReSKiTE aims to estimate and compare relative survival from cancer diagnosis (all-cause and cancer subtypes) between kidney failure patients, kidney transplant recipients and the general population. Study findings will provide insight into whether survival is comparable to the general population.